Filing Analysis
ImageneBio, Inc. announced its financial results for the fiscal quarter ended June 30, 2026. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2026
- Announcement date: August 5, 2026
- The company is classified as an 'emerging growth company' under SEC rules.
ImageneBio, Inc. has appointed Yanina Grant-Huerta as Chief Financial Officer, effective July 20, 2026, replacing the interim CFO role held by CEO Kristin Yarema. Additionally, CMO Benjamin Porter-Brown will transition to a consulting role effective July 24, 2026.
🚩 Red Flags
- Transition of CMO from full-time to consultant (though framed as staying committed).
📋 Key Facts
- Yanina Grant-Huerta appointed as CFO, Principal Financial Officer, and Principal Accounting Officer on July 20, 2026.
- Grant-Huerta's compensation includes a $450,000 base salary and a 40% discretionary bonus target.
- Equity incentives include 65,000 RSUs and 95,000 stock options under the 2025 Equity Inducement Plan.
- Grant-Huerta previously served as Chief Accounting Officer at Atara Biotherapeutics and held various roles at Amgen Inc.
- CMO Benjamin Porter-Brown transitioning to a consulting role effective July 24, 2026.
ImageneBio, Inc. announced the resignation of Robert Lally, Senior Vice President of Finance and Operations and principal accounting officer, effective July 22, 2026.
🚩 Red Flags
- Departure of the Principal Accounting Officer (PAO) can sometimes precede financial restatements or internal control issues, though no disagreement was cited here.
📋 Key Facts
- Robert Lally is resigning from his role as SVP of Finance and Operations and Principal Accounting Officer.
- The resignation became effective on June 22, 2026, with a formal departure date of July 22, 2026.
- The company stated the resignation was not due to any disagreement with the Company.
- A search for a replacement is currently underway.
ImageneBio, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 16, 2026. Stockholders elected two Class II directors, ratified the appointment of PwC as the independent auditor, and approved an amendment to the 2025 Equity Incentive Plan.
📋 Key Facts
- Stockholders approved an amendment to the 2025 Equity Incentive Plan, increasing authorized common stock for issuance by 850,000 shares.
- David P. Bonita, M.D. and Joseph P. Slattery were elected as Class II directors with terms ending at the 2029 Annual Meeting.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- The record date for the meeting was April 28, 2026, with 11,279,130 outstanding shares of voting common stock.
ImageneBio, Inc. reported its financial results for the first quarter ended March 31, 2026. The announcement was made via a press release furnished as an exhibit to the 8-K filing.
📋 Key Facts
- Financial results cover the quarter ended March 31, 2026
- The report was filed on May 7, 2026
- Information was furnished under Item 2.02 (Results of Operations and Financial Condition)
- Kristin Yarema, Ph.D., serves as the Chief Executive Officer
ImageneBio, Inc. entered into a securities purchase agreement for a $30 million private placement of pre-funded warrants with institutional and accredited investors. The capital is earmarked for late-phase development of their atopic dermatitis program and expanding clinical trials for IMG-007 into alopecia areata.
🚩 Red Flags
- Private placement (PIPE) transactions can result in significant dilution for existing shareholders.
- The registration statement filing is delayed until August 1, 2026, which may impact liquidity for the new investors.
📋 Key Facts
- Agreement signed on April 12, 2026, for a private placement of pre-funded warrants.
- Total gross proceeds of approximately $30 million.
- Issuance of 5,770,335 pre-funded warrants at a purchase price of $5.199 per warrant.
- The warrants have an exercise price of $0.001 and no expiration date.
- Company committed to filing a resale registration statement by August 1, 2026.
- Beneficial ownership is limited to 19.99% for any single holder.
ImageneBio, Inc. announced the mutual separation of Erin Butler, its SVP of Finance and Principal Accounting Officer, effective March 20, 2026. The company has appointed Bob Lally, the current SVP of Finance & Operations, to succeed her as the Principal Accounting Officer.
🚩 Red Flags
- Departure of the Principal Accounting Officer (PAO), which is a key role for financial reporting integrity.
- The use of the term 'mutual separation' can sometimes indicate underlying disagreements, though none are explicitly stated.
📋 Key Facts
- Erin Butler will depart as SVP, Finance & Administration and Principal Accounting Officer on March 20, 2026.
- The separation is described as a 'mutual separation'.
- Bob Lally, age 63, is appointed as the new Principal Accounting Officer effective March 20, 2026.
- Bob Lally has served as SVP, Finance & Operations since July 2025 and previously held senior roles at Prevail Therapeutics and Arsanis, Inc.
- Ms. Butler will receive severance benefits pursuant to a Severance Rights Agreement dated October 21, 2024.
ImageneBio, Inc. announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The results were furnished via a press release attached as Exhibit 99.1.
📋 Key Facts
- Reporting period covers the fiscal year and quarter ended December 31, 2025
- Filing date: March 10, 2026
- Item 2.02 (Results of Operations and Financial Condition) triggered
- Kristin Yarema, Ph.D. signed as Chief Executive Officer
ImageneBio, Inc. announced the immediate resignation of Steven Hui Wang from its Board of Directors on February 12, 2026.
📋 Key Facts
- Steven Hui Wang resigned as a member of the Board of Directors effective February 12, 2026.
- The company stated the resignation was not due to any disagreement regarding operations, policies, practices, or strategy.
ImageneBio, Inc. announced the resignation of its Chief Medical Officer, Yufang Lu, M.D., Ph.D., effective December 31, 2025. The company stated the departure is not due to any disagreements regarding operations or policies and has initiated a search for a successor.
📋 Key Facts
- Yufang Lu, M.D., Ph.D., resigned as Chief Medical Officer on December 12, 2025.
- Resignation becomes effective on December 31, 2025.
- The departure is not related to any disagreements regarding company operations, policies, or practices.
- Dr. Lu will provide transition advisory services after her official resignation date.
ImageneBio, Inc. has updated its corporate presentation to be used in meetings with investors and analysts. This filing is a routine disclosure of non-material information under Regulation FD.
📋 Key Facts
- Company updated its corporate presentation on November 19, 2025.
- The presentation is intended for use in meetings with investors, analysts, and other stakeholders.
- The update was published via Item 7.01 (Regulation FD Disclosure).
ImageneBio, Inc. announced its financial results for the quarter ended September 30, 2025. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2025
- Announcement date: November 12, 2025
- The company is classified as an 'emerging growth company' under the Securities Act of 1933.
ImageneBio, Inc. announced an expansion of its Board of Directors from six to seven members with the appointment of Joseph P. Slattery. Mr. Slattery will serve as a Director effective November 1, 2025, and assume Chair of the Audit Committee on November 18, 2025.
📋 Key Facts
- Board size increased from six to seven directors.
- Joseph P. Slattery appointed to the Board effective November 1, 2025.
- Mr. Slattery to assume Chair of the Audit Committee on November 18, 2025.
- Standard indemnification agreement entered into with Mr. Slattery.
ImageneBio, Inc. has modified its transition services agreement with Miragene Inc., electing not to renew the full original agreement but instead extending a subset of services for six months.
🚩 Red Flags
- Reduction in scope of transition services may indicate a phase-out of reliance on an external entity/parent company.
- The shift from full renewal to a limited 6-month extension suggests a transitional period where the company is attempting to stand alone or wind down specific dependencies.
📋 Key Facts
- The company provided written notice on October 23, 2025, regarding the termination/modification of a transition services agreement dated July 25, 2025.
- The original Agreement with Miragene Inc. will not automatically renew under current terms.
- A subset of services (CMC, translational sciences research and support) will be extended for six months ('Miragene Extension Services').
- Total fees payable for the extension services are $200,000.
ImageneBio, Inc. has appointed its current CEO, Kristin Yarema, Ph.D., to serve as the interim Principal Financial Officer (PFO) effective October 21, 2025.
🚩 Red Flags
- Dual role assumption (CEO acting as PFO) often indicates a sudden vacancy in the finance department or lack of resources to hire a permanent CFO/PFO immediately.
- Potential internal control weakness if the transition was unplanned.
📋 Key Facts
- Effective Date: October 21, 2025
- New Role: Dr. Kristin Yarema appointed as Interim Principal Financial Officer (PFO)
- Current Role: Dr. Kristin Yarema remains Chief Executive Officer (CEO)
- Company is an emerging growth company
ImageneBio, Inc. announced the resignation of its Chief Financial Officer (CFO) and principal financial officer, Jotin Marango, M.D., Ph.D., effective October 20, 2025. The company stated the departure is not due to any disagreement with the firm.
🚩 Red Flags
- Sudden departure of a key executive (CFO) in a micro-cap biotech environment can sometimes precede financial scrutiny, though no disagreement was noted here.
📋 Key Facts
- Jotin Marango, M.D., Ph.D., resigned as CFO and principal financial officer on October 10, 2025.
- The resignation becomes effective on October 20, 2025.
- The company explicitly stated the resignation was not due to any disagreement with the Company.
- A search for a replacement is currently underway.
ImageneBio, Inc. (formerly Ikena Oncology, Inc.) filed an amendment to its 8-K to include the Management's Discussion and Analysis (MD&A) and unaudited interim financial statements for Inmagene following a completed merger/acquisition.
🚩 Red Flags
- Post-merger reporting delays/amendments can sometimes indicate complexities in integrating financial data or accounting reconciliations between the two entities.
📋 Key Facts
- The filing is an Amendment No. 1 to an original 8-K filed on July 29, 2025.
- The amendment provides MD&A for Inmagene for the three and six months ended June 30, 2025, and 2024.
- Includes unaudited interim condensed financial statements of Inmagene as of and for the periods ending June 30, 2025, and 2024.
- The company's name has changed from Ikena Oncology, Inc. to ImageneBio, Inc.
ImageneBio, Inc. has dismissed Ernst & Young LLP (EY) as its independent registered public accounting firm and appointed PricewaterhouseCoopers LLP (PwC) effective August 2, 2025.
🚩 Red Flags
- Auditor change (EY dismissal) can sometimes precede restatements or internal control issues, though no disagreements were reported here.
📋 Key Facts
- Dismissal of EY became effective on August 2, 2025.
- Appointment of PwC for the fiscal year ending December 31, 2025.
- EY's audit reports for FY2023 and FY2024 did not contain adverse opinions or disclaimers.
- The Company stated there were no disagreements with EY regarding accounting principles, practices, or auditing procedures.
- PwC previously served as the auditor for Inmagene Biopharmaceuticals prior to its merger with the Company.
ImageneBio, Inc. has approved a 2025 Inducement Plan to reserve 589,585 shares of common stock for recruiting new employees and directors via equity awards.
🚩 Red Flags
- Potential dilution of existing shareholders through the issuance of new equity awards.
📋 Key Facts
- The Board adopted the 2025 Inducement Plan on July 28, 2025.
- The plan reserves 589,585 shares of common stock.
- Shares are intended for equity awards (Stock Options and RSUs) to non-employees/directors or returning employees.
- The plan was approved without stockholder approval per Nasdaq Listing Rule 5635(c)(4).
Ikena Oncology, Inc. (now ImageneBio, Inc.) has completed its merger with Inmagene Biopharmaceuticals, resulting in a complex corporate restructuring involving the creation of Contingent Value Rights (CVRs) for both legacy shareholder groups and the establishment of transition services agreements.
🚩 Red Flags
- Complex CVR structures create potential long-term liabilities and uncertainty for legacy shareholders.
- Transition Services Agreement involves 'SellCo', which is controlled by Inmagene's former management and major shareholders (Related Party Transaction).
- The company has significant future milestone payment obligations to Hutchmed under the Hutchmed Collaboration Agreement, totaling up to $227.5 million.
📋 Key Facts
- Merger completion date: July 25, 2025.
- Company name changed from Ikena Oncology, Inc. to ImageneBio, Inc.
- Two separate CVR Agreements were entered into: one for Ikena shareholders and one for Inmagene shareholders.
- Ikena CVR holders receive 100% of net proceeds from pre-merger asset dispositions (e.g., IK-595) and 90% of post-closing disposition proceeds during a 'Disposition Period'.
- Inmagene CVR holders receive 100% of net proceeds from pre-merger asset dispositions (excluding IMG-007) and 90% of post-closing proceeds during the Disposition Period.
- A Transition Services Agreement was signed with SellCo to support the ongoing operations of the IMG-007 program for an initial term of six months.
- The Company paid $1.25 million as a pre-payment for Miragene Services under the Transition Services Agreement.
Ikena Oncology, Inc. completed its merger with Inmagene Biopharmaceuticals on July 25, 2025, resulting in the company changing its name to ImageneBio, Inc. The transaction involved a two-step merger structure involving Cayman Islands subsidiaries.
🚩 Red Flags
- Complex two-step merger structure involving offshore (Cayman Islands) entities
📋 Key Facts
- Merger completion date: July 25, 2025
- Company name change from Ikena Oncology, Inc. to ImageneBio, Inc.
- The transaction was executed via a two-step merger involving Insight Merger Sub I and Insight Merger Sub II
- Inmagene Biopharmaceuticals is an exempted company incorporated in the Cayman Islands
- The original merger agreement was dated December 23, 2024
Ikena Oncology, Inc. announced a 1-for-12 reverse stock split to facilitate its merger with Inmagene Biopharmaceuticals. The transaction will result in the company rebranding as ImageneBio, Inc. (ticker: IMA) on the Nasdaq Capital Market.
🚩 Red Flags
- Reverse stock split (Red flag escalator).
- Significant reduction in share count/liquidity profile via consolidation.
- Implicit mention of 'risks related to the inability... to obtain sufficient additional capital' in forward-looking statements.
📋 Key Facts
- Reverse split ratio is 1-for-12.
- Expected trading on a post-reverse basis starts July 28, 2025.
- Company will change name to ImageneBio, Inc. and ticker to IMA.
- Outstanding shares expected to decrease from ~48.2 million to ~4 million.
- Fractional shares will be paid out in cash based on the July 24, 2025 closing price.
Ikena Oncology has announced the issuance of a one-time special dividend in the form of Contingent Value Rights (CVRs) to existing stockholders. This action is part of the ongoing merger process with Inmagene Biopharmaceuticals, intended to distribute potential future proceeds from pre-merger asset dispositions.
🚩 Red Flags
- No guarantee of payment; CVRs may expire worthless if no milestone/royalty proceeds are realized.
📋 Key Facts
- Board approved issuance of one CVR for each outstanding share of Ikena common stock.
- Record date for CVR eligibility is the close of business on July 24, 2025.
- CVR holders are entitled to 100% of net proceeds from milestone, royalty, or earnout payments related to pre-merger assets (e.g., IK-595).
- The CVR structure includes a provision for 90% of net proceeds from disposition agreements entered into after the merger closing but before the first anniversary.
- CVR payments are subject to deductions for taxes, expenses, and wind-down costs.
Ikena Oncology entered into an amendment to the employment agreement for Dr. Jotin Marango, providing accelerated vesting of equity awards in the event of a termination without cause or resignation during a change-in-control period.
🚩 Red Flags
- Potential for significant dilution/payouts if a merger occurs, as equity awards will accelerate upon change in control.
📋 Key Facts
- Amendment effective as of July 15, 2025.
- Covers Dr. Jotin Marango's employment agreement regarding benefits during a 'change in control period'.
- The 'change in control period' began on March 18, 2025, following the filing of an S-4 related to a contemplated merger with Inmagene Biopharmaceutics.
- Provides for accelerated vesting of all time-based stock options and equity awards upon termination without cause or resignation during the change in control period.
- The change in control period ends 12 months after the effective date of the contemplated merger.
Ikena Oncology, Inc. announced that stockholders approved a 1-for-12 reverse stock split and the merger with Inmagene Biopharmaceuticals. The combined entity will trade as 'ImageneBio, Inc.' under the ticker 'IMA' following the transaction expected in late July 2025.
🚩 Red Flags
- Reverse stock split (1-for-12) often used to maintain exchange listing requirements or manage share price.
- The merger involves a change of control and issuance of new shares representing >20% of outstanding common stock.
📋 Key Facts
- Stockholders approved a 1-for-12 reverse stock split of Ikena common stock.
- The merger with Inmagene Biopharmaceuticals is expected to close around the end of July 2025.
- Post-split, outstanding shares are expected to decrease from ~48.2 million to ~4 million (excluding merger issuances).
- The combined company will trade on Nasdaq as 'ImageneBio, Inc.' with ticker 'IMA'.
- Stockholders of record entitled to fractional shares will receive cash payments in lieu of shares.
Ikena Oncology announced that major proxy advisory firms ISS and Glass Lewis have recommended that stockholders vote 'FOR' the proposed merger with Inmagene Biopharmaceuticals. The shareholder vote is scheduled for July 15, 2025.
🚩 Red Flags
- Potential dilution for existing shareholders due to the issuance of new shares in connection with the merger.
- Uncertainty regarding 'concurrent financing' mentioned in forward-looking statements which may impact ownership structure and cash runway.
📋 Key Facts
- Proxy advisors Institutional Shareholder Services (ISS) and Glass, Lewis & Co. recommend a 'FOR' vote regarding the issuance of shares for the merger.
- The Annual Meeting of Stockholders is scheduled for July 15, 2025.
- The transaction involves a two-step merger structure involving Merger Sub I and Merger Sub II to absorb Inmagene Biopharmaceuticals.
- The merger was originally entered into via an Agreement and Plan of Merger on December 23, 2024.
Ikena Oncology announced that its target company, Inmagene Biopharmaceuticals, has successfully dosed the first patient in its Phase 2b ADAPTIVE clinical trial for IMG-007. This update follows a previously announced merger agreement between Ikena and Inmagene.
🚩 Red Flags
- Clinical trial risk: The success of the merger is tied to the clinical development and potential regulatory approval of Inmagene's product candidates, specifically IMG-007.
- Integration/Closing Risk: Potential for failure to obtain shareholder approval or satisfy closing conditions for the merger.
📋 Key Facts
- Inmagene successfully dosed the first patient in the global multicenter Phase 2b dose-finding study (ADAPTIVE Trial, NCT07037901) for IMG-007.
- The trial targets patients with moderate-to-severe atopic dermatitis (AD).
- Ikena Oncology is in the process of acquiring Inmagene via a merger involving two Cayman Islands subsidiaries (Merger Sub I and II).
- The Merger Agreement was originally entered into on December 23, 2024.
Ikena Oncology, Inc. has entered into a definitive merger agreement to acquire Inmagene Biopharmaceuticals through a two-step merger structure. The transaction includes a significant PIPE financing of approximately $75 million and will result in a combined entity where pre-merger Inmagene equityholders hold a majority stake.
🚩 Red Flags
- Reverse Stock Split: The merger agreement includes a proposal to amend the certificate of incorporation to effect a reverse stock split if deemed necessary for Nasdaq listing.
- Dilution: Significant dilution for existing Ikena shareholders due to both the Inmagene acquisition and the $75M PIPE financing.
- Complexity: Two-step merger structure involving Cayman Islands entities increases execution risk.
📋 Key Facts
- Transaction Structure: Two-step merger involving Merger Sub I and Merger Sub II; intended to be a tax-free reorganization.
- Ownership Post-Merger (Pre-PIPE): Pre-merger Inmagene equityholders will own ~55.6%; pre-merger Ikena equityholders will own ~44.4%.
- Ownership Post-Merger (Post-PIPE): Pre-merger Inmagene holders ~43.5%, pre-merger Ikena holders ~34.8%, and PIPE investors ~21.7%.
- Financing: Approximately $75,000,000 PIPE Financing is expected to accompany the closing.
- Contingent Value Rights (CVR): Ikena stockholders will receive one CVR for each share held, providing rights to 100% of net proceeds from certain milestone/royalty payments on pre-merger assets like IK-595.
- Closing Condition: Ikena must have a minimum of $95,000,000 in net cash if closing occurs before May 1, 2025.
Ikena Oncology, Inc. announced the promotion of Jotin Marango, M.D., Ph.D. to Chief Operating Officer, effective July 15, 2024. Dr. Marango will retain his existing roles as Chief Financial Officer and Head of Corporate Development.
🚩 Red Flags
- The vesting of 400,000 stock options is tied specifically to the 'consummation of a strategic transaction', which may signal management's focus on M&A or a sale of the company.
📋 Key Facts
- Jotin Marango appointed COO effective July 15, 2024.
- Dr. Marango will continue to serve as CFO and Head of Corporate Development.
- Annual salary increased to $470,000 effective July 15, 2024.
- Granted an option to purchase 400,000 shares of common stock, vesting upon the consummation of a strategic transaction.
Ikena Oncology, Inc. held its Annual Meeting of Stockholders on June 7, 2024. The meeting resulted in the successful election of two Class III directors and the ratification of Ernst & Young LLP as the company's independent auditor.
📋 Key Facts
- Annual Meeting held on June 7, 2024.
- Owen Hughes was elected to the Board of Directors (Class III) with 22,250,184 votes in favor.
- Mark Manfredi, Ph.D. was elected to the Board of Directors (Class III) with 24,738,833 votes in favor.
- Stockholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- As of April 10, 2024, there were 41,889,525 outstanding shares of voting common stock.
Ikena Oncology has announced a significant restructuring plan involving the discontinuation of its IK-930 clinical program and a 53% reduction in workforce. Additionally, the Board is exploring strategic alternatives including potential mergers, acquisitions, or asset sales.
🚩 Red Flags
- Significant workforce reduction (53%) indicates severe capital constraints or pivot in strategy.
- Discontinuation of a clinical program (IK-930) suggests failure to meet development milestones or lack of funding for that asset.
- Exploration of 'strategic options' often signals a company seeking an exit due to limited runway.
📋 Key Facts
- Discontinuation of clinical development for IK-930.
- Continued clinical development of IK-595.
- Workforce reduction of approximately 53% (terminating ~18 employees).
- Expected post-restructuring headcount: ~16 full-time employees.
- Estimated $1.2 million in cash expenditures for severance and termination benefits in Q2 2024.
- Board is evaluating strategic options including acquisition, merger, reverse merger, or sale of assets.
Ikena Oncology announced the resignation of its Chief Medical Officer, Dr. Sergio Santillana, effective February 29, 2024. The company has simultaneously appointed Dr. Caroline Germa as the new Chief Medical Officer to ensure leadership continuity.
🚩 Red Flags
- Departure of a key C-suite executive (Chief Medical Officer) in a clinical-stage biotech company.
📋 Key Facts
- Dr. Sergio Santillana is resigning as CMO effective Feb 29, 2024; last day of employment is March 5, 2024.
- The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Dr. Santillana will transition to a part-time consultant role for up to 9 months (ending Dec 31, 2024).
- Consulting compensation includes $500 per hour and a one-time retainer of $15,735.96.
- Dr. Caroline Germa has been appointed as the new Chief Medical Officer, effective Feb 29, 2024.
Ikena Oncology announced a significant workforce reduction of approximately 35% to pivot focus toward its clinical-stage oncology programs. Additionally, the company regained full global rights to two programs (IK-175 and IK-412) after Bristol Myers Squibb declined to opt-in.
🚩 Red Flags
- Significant workforce reduction (35%) indicating a major strategic pivot or cost-cutting measure.
- Loss of collaboration/opt-in from a major partner (Bristol Myers Squibb) for two programs.
- Discontinuation of investment in the clinical development of IK-175 and IK-412.
📋 Key Facts
- Workforce reduction of approximately 35% (approx. 20 employees) expected to be completed by March 31, 2024.
- Post-reduction headcount will be approximately 37 full-time employees.
- Estimated cash, cash equivalents, and marketable securities: ~$175 million as of Dec 31, 2023.
- Workforce reduction expected to extend cash runway into the second half of 2026.
- Expected exit costs related to workforce reduction: ~$1.6 million in cash expenditures.
- Bristol Myers Squibb declined to opt-in for the IK-175 and IK-412 programs, returning full global rights to Ikena Oncology.